Company invites individual and institutional investors as well as advisors to attend interactive real-time virtual VirtualInvestorConferences.com
JACKSONVILLE, Fla., Jan. 30, 2017 /CNW/ -- TapImmune, Inc (NASDAQ: TPIV), a clinical-stage immuno-oncology company specializing in the development of innovative peptide and gene-based immunotherapeutics for the treatment of cancer and metastatic disease, today announced that Glynn Wilson, Chief Executive Officer and Dr John Bonfiglio, Chief Operating Officer, will present live at VirtualInvestorConferences.com on February 2, 2017.
DATE: Thursday, February 2, 2017
TIME: 12:15pm Eastern Time
This will be a live, interactive online event where investors are invited to ask the company questions in real-time - both in the presentation hall as well as the association's "virtual trade booth." If attendees are not able to join the event live on the day of the conference, an on-demand archive will be available for 90 days.
It is recommended that investors pre-register and run the online system check to save time and receive event updates.
Learn more about the event at www.VirtualInvestorConferences.com.
TapImmune Corporate Highlights
- Potential to be dominant player in T-cell cancer vaccines by eliciting both helper and killer T-cell responses
- Evaluating lead candidate in four Phase 2 studies, some with FDA Fast Track and Orphan Disease Status
- Highly vetted technology: Collaborations with Mayo Clinic, AstraZeneca, Memorial Sloan Kettering Cancer Center, U.S. Dept. of Defense
- Compelling Phase 1 data show robust and enduring immune response against vaccine targets
- Multiple upcoming clinical value inflection points
About TapImmune, Inc.
TapImmune Inc. is a clinical-stage immuno-oncology company specializing in the development of innovative peptide and gene-based immunotherapeutics for the treatment of cancer and metastatic disease. The Company's peptide or nucleic acid-based immunotherapeutics comprise one or multiple naturally processed epitopes (NPEs) designed to comprehensively stimulate patients' killer T-cells and helper T-cells, or to restore or further augment antigen presentation by using proprietary nucleic acid-based expression systems. The Company's technologies may be used as stand-alone medications or in combination with current treatment modalities, including immune checkpoint inhibitors.
Please visit the Company's website at www.tapimmune.com for more details.
Since 2010, VirtualInvestorConferences.com, created by BetterInvesting (NAIC) and PRNewswire, has been the only monthly virtual investor conference series that provides an interactive forum for presenting companies to meet directly with investors using a graphically-enhanced online platform.
Designed to replicate the look and feel of location-based investor conferences, Virtual Investor Conferences unites PR Newswire's leading-edge online conferencing and investor communications capabilities with BetterInvesting's extensive retail investor audience network.
SOURCE TapImmune, Inc.
To view this news release in HTML formatting, please use the following URL: http://www.newswire.ca/en/releases/archive/January2017/30/c7606.html
For further information: TapImmune, Inc.: TapImmune Inc., Glynn Wilson, Ph.D., Chairman & CEO, (866)-359-7541, email@example.com; VirtualInvestorConferences.com: Bradley H. Smith, Director of Marketing, IR and Compliance Services; PR Newswire: +1.201.947.7157, firstname.lastname@example.org, http://www.tapimmune.com